Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoni, Matteo, Massari, Francesco, Bracarda, Sergio, Procopio, Giuseppe, Milella, Michele, De Giorgi, Ugo, Basso, Umberto, Aurilio, Gaetano, Incorvaia, Lorena, Martignetti, Angelo, Rizzo, Mimma, Cartenì, Giacomo, Grande, Enrique, Matrana, Marc R., Crabb, Simon J., Vau, Nuno, Sorgentoni, Giulia, Cimadamore, Alessia, Montironi, Rodolfo, Battelli, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831923/
https://www.ncbi.nlm.nih.gov/pubmed/33477676
http://dx.doi.org/10.3390/diagnostics11010138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831923/
https://www.ncbi.nlm.nih.gov/pubmed/33477676
http://dx.doi.org/10.3390/diagnostics11010138

Ejemplares similares